Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma

NCT03406247 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris